Intervention
raltegravir
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 26 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownA Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, TexasNCT02302950 · 2014-09-01
UNKNOWNPharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).NCT01978782 · 2014-01-01
COMPLETEDPharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.NCT01779687 · 2013-03-01
COMPLETEDRAltegravir Switch STudy: Effects on Endothelial RecoveryNCT01453933 · 2012-01-01
UNKNOWNEffects of Intensive cART During Acute/Early HIV InfectionNCT01154673 · 2011-11-01
COMPLETEDPharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirNCT01288417 · 2011-08-01
COMPLETEDInterferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsNCT01285050 · 2011-01-01
COMPLETEDA Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyNCT01227824 · 2010-10-19
COMPLETEDSafety Study of Raltegravir in HIV/HCV Co-infected PatientsNCT01225705 · 2010-10-01
WITHDRAWNEfficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese PatientsNCT01201239 · 2010-09-01
UNKNOWNPharmacokinetics of Low Dose RaltegravirNCT01159132 · 2010-04-01
COMPLETEDBone and Body Comp: A Sub Study of the SECOND-LINE StudyNCT01513122 · 2010-02-01
COMPLETEDA Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenNCT00931463 · 2009-09-01
COMPLETEDEffect of Antacids on the Pharmacokinetics of RaltegravirNCT00944307 · 2009-07-01
COMPLETEDEfficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisNCT00822315 · 2009-07-01
COMPLETEDChanges in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard TherapyNCT00887653 · 2009-05-01
COMPLETEDPilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductNCT00773708 · 2009-03-01
COMPLETEDEffect of Raltegravir on Endothelial Function in HIV-Infected PatientsNCT00843713 · 2009-01-01
COMPLETEDRaltegravir Therapy for Women With HIV and Fat AccumulationNCT00656175 · 2008-09-01
COMPLETEDPilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the GutNCT00884793 · 2008-09-01
COMPLETEDRaltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 PatientsNCT00672932 · 2008-04-01
COMPLETEDBRAVO: Background Regimen of Raltegravir on Virologic OutcomeNCT00751530 · 2008-03-01
COMPLETEDPilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir TherapyNCT00661960 · 2008-03-01
COMPLETEDEvaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected SubjectsNCT00529243 · 2007-09-01
COMPLETEDPharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After PregnancyNCT00042289 · 2003-06-09
COMPLETEDEarly Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)NCT00377065
APPROVED_FOR_MARKETINGCommon conditions
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
Radboud University Medical Center
3
University of California, San Francisco
3
Kirby Institute
2
ANRS, Emerging Infectious Diseases
1
Community Research Initiative of New England
1
Germans Trias i Pujol Hospital
1
Johns Hopkins University
1
Kaiser Permanente
1
Merck Sharp & Dohme LLC
1
National Institute of Allergy and Infectious Diseases (NIAID)
1
Shanghai Public Health Clinical Center
1
The HIV Netherlands Australia Thailand Research Collaboration
1
The Miriam Hospital
1
The University of Texas Health Science Center, Houston
1
UMC Utrecht
1
Trial status mix
COMPLETED21
UNKNOWN3
APPROVED_FOR_MARKETING1
WITHDRAWN1
Phase mix
PHASE48
PHASE14
PHASE24
PHASE34
NA3
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.